Antisense

In a study reported in the journal Science Translational Medicine, researchers describe how a synthetic drug, called antisense oligonucleotide, reduced the production and in some cases cleared clumps of tau in the brain.

Other types of antisense oligonucleotides have been approved by U.S. regulators and are being used to treat the neurodegenerative disease muscular dystrophy and spinal muscular atrophy. The compound is in clinical trials for Huntington’s disease and ALS, also known as Lou Gehrig’s disease.